Similarly, several promising therapeutic targets have been identified using the NPcis MPNST mouse model, including epidermal growth factor receptory (EGFR) and mechanistic target of rapamycin (mTOR), but none have demonstrated activity in clinical trials for MPNST [14,93,94]. This evidence concerns the gene MTOR and malignant peripheral nerve sheath tumor.